AbbVie to Buy ImmunoGen for More Than $10 Billion

Nov. 30, 2023 7:51 am ET

AbbVie has agreed to buy ImmunoGen for about $10.1 billion in a deal that speeds the biopharmaceutical company’s entry into the commercial market for ovarian cancer.

AbbVie on Thursday said it will pay $31.26 a share in cash for ImmunoGen, a roughly 95% premium to Wednesday’s closing price of $16.06 for the Waltham, Mass., pharmaceutical company.

Source: finance.yahoo.com

If You'd Invested $1,000 in Starbucks Stock 20 Years Ago, Here's How Much You'd Have Today

Analyst Report: Shopify Inc

NVIDIA Corp. Shares Have Further to Go, Supported by Growing Sales

Billionaire Bill Ackman Has Almost 20% of His Pershing Square Portfolio Invested in This "Magnificen...

Investors are making the wrong bet on a recession — and it's going to cost them big time